---
title: "LENSAR terminates Alcon merger as FTC moves to block the deal"
url: "https://aibio.space/news/lensar-terminates-alcon-merger-ftc-moves-block-deal/"
event_date: "2026-03-16"
date_published: "2026-11-08"
description: "LENSAR and Alcon Research terminated their merger agreement on March 16, 2026. LENSAR keeps a $10.0 million deposit after the Federal Trade Commission signaled a court challenge."
---

# LENSAR terminates Alcon merger as FTC moves to block the deal

LENSAR, Inc. (Nasdaq: LNSR) agreed on March 16, 2026 to terminate the merger agreement it signed with Alcon Research, LLC on March 23, 2025. The companies disclosed the termination in a [Form 8-K dated March 16, 2026](https://www.sec.gov/Archives/edgar/data/1320350/000119312526109458/d27242d8k.htm). LENSAR said it understood that the Federal Trade Commission intends to seek to enjoin the acquisition. Under the termination agreement, LENSAR keeps the $10.0 million deposit that Alcon made under the merger agreement.

Why is this important: Alcon had agreed to pay $14.00 per share in cash, plus a contingent value right of up to $2.75 per share. That cash price is now gone for shareholders. LENSAR goes back to running its own business, a company that its 10-Q describes as having incurred recurring losses and operating cash outflows since its inception. The $10.0 million deposit is what the company keeps from the failed deal.

Nicholas T. Curtis, the chief executive officer, signed the Form 8-K. In our view, the board and management spent most of a year on a sale that the Federal Trade Commission intended to challenge in court, and shareholders carried that uncertainty the whole time. Cash and cash equivalents fell from $16,263 thousand at December 31, 2024 to $7,637 thousand at September 30, 2025, and the company's 10-Q reports recurring losses since its inception.

## What the termination means for LENSAR's cash

The merger agreement depended on U.S. regulatory approvals. LENSAR and Alcon said that condition was unlikely to be met by the outside date of April 23, 2026, or by the potential extended outside date of July 23, 2026. The termination ends that timetable, and the two companies released each other from claims tied to the agreement.

The company filed the termination under Item 1.02 of Form 8-K, the item for the termination of a material definitive agreement. It also furnished the press release under Item 7.01 and attached the termination agreement as Exhibit 10.1. The filing describes the terminated transaction as the Merger, with VMI Option Merger Sub, Inc. as the Alcon subsidiary that would have merged into LENSAR.

The [Form 10-Q for the quarter ended September 30, 2025](https://www.sec.gov/Archives/edgar/data/1320350/000119312525269428/lnsr-20250930.htm) reports cash and cash equivalents of $7,637 thousand and short-term investments of $9,232 thousand. It shows an accumulated deficit of $176.1 million. Net cash used in operating activities was $15,449 thousand for the nine months ended September 30, 2025. The company said it expects to keep incurring losses and cash outflows from operating activities in the near term.

The deposit is a single payment tied to a deal that did not close. In our view, it does not change the operating losses the 10-Q describes, and it leaves the company to fund its plans from its own balance sheet.

The merger terms were set out in the 10-Q note on the agreement. Alcon agreed to pay $14.00 per share in cash, and each share also carried one contingent value right for a payment of $2.75 in cash upon achievement of 614,000 cumulative procedures with the company's products between January 1, 2026 and December 31, 2027. The termination removes both payments. The company said the parties agreed that ending the deal at this time was in the best interest of both companies.

## The ALLY laser and what comes next

LENSAR's lead product is the ALLY Robotic Cataract Laser System. The March 16 release says the company introduced ALLY commercially in 2022 and remains committed to advancing cataract surgery through the continued market growth of the system. The filings cited here name no clinical trial and no ClinicalTrials.gov number for ALLY, and they set no regulatory milestone for the product.

The release says the company will share more detail on its go-forward strategy when it reports financial results on March 31, 2026. That is the next dated event the company has named. The release also lists the risk of litigation related to the terminated merger among its forward-looking risks, and it points to the Annual Report on Form 10-K for the year ended December 31, 2025, which the company said it would file.

The company's own [press release dated March 16, 2026](https://www.sec.gov/Archives/edgar/data/1320350/000119312526109458/d27242dex991.htm) gives the parties' wording on the termination.

Sources

- https://www.sec.gov/Archives/edgar/data/1320350/000119312526109458/d27242d8k.htm
- https://www.sec.gov/Archives/edgar/data/1320350/000119312526109458/d27242dex991.htm
- https://www.sec.gov/Archives/edgar/data/1320350/000119312525269428/lnsr-20250930.htm
